BIIB trades against a final fair-value range of $192.23-$314.03, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs. Fair value range: low $192, high $314, with mid-point at $253.
Trades below fair value with a meaningful cushion to the midpoint.
Fair value
$253
Margin of safety
+21.2%
Confidence
83/100
Moat
6.5/10
Educational analysis only — not financial advice. Always do your own due diligence.
$199.36Price
Low $192.23
Mid $253.08
High $314.03
BIIB trades against a final fair-value range of $192.23-$314.03, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.
Legacy MS franchise cash flows
Legacy MS franchise cash flows
Alzheimer's first-mover pipeline (Leqembi)
Alzheimer's first-mover pipeline (Leqembi)
Cycle upside
Alzheimer's therapeutic breakthrough scaling.
§2 Bear case
Leqembi adoption is stunted by administration bottlenecks or safety concerns while the MS franchise erodes faster than modeled, forcing sustained margin compression and multiple degradation.
Ways this thesis can break
Leqembi Market Rejection
· Medium
Severe administration bottlenecks and ARIA safety concerns permanently stunt Leqembi uptake.
FV impact
-30%
Accelerated Generic MS Erosion
· High
Legacy MS products lose market share far faster than expected, crashing trailing cash flows before pipeline kicks in.
FV impact
-25%
Adverse Regulatory Pricing
· Low
Global structural drug pricing pressures disproportionately target Biogen's high-margin neurology portfolio.
Based on our latest analysis, BIIB looks meaningfully undervalued. The current price is $199 versus a composite fair-value midpoint of $253 (range $192–$314), which implies roughly 26.9% upside to the midpoint.
Our composite fair-value range for BIIB is $192–$314, with a midpoint of $253. The range is triangulated across multiple valuation models (discounted earnings, forward earnings scenarios, peer multiples, and where applicable owner earnings or reverse DCF) and weighted by reliability for BIIB's archetype.
Our current rating for BIIB is Strong Buy with a confidence score of 83/100. BIIB is rated Strong Buy at $199.36 versus the reconciled fair value midpoint of $253.08, implying +26.95% upside/downside. Confidence is separately disclosed at 83/100. This is research for educational purposes, not personalized investment advice.
The top risks our latest report flags for BIIB are: Leqembi Market Rejection; Accelerated Generic MS Erosion; Adverse Regulatory Pricing. The single biggest risk is Leqembi Market Rejection: Severe administration bottlenecks and ARIA safety concerns permanently stunt Leqembi uptake.
Our current rating for BIIB is Strong Buy, issued with a confidence score of 83/100 and a moat score of 6.5/10. The rating reflects the composite fair-value range ($192–$314) versus the current price of $199.
BIIB is classified as a mature compounder stock. Archetype determines how every downstream parameter — discount rate, terminal growth, deceleration curve, terminal multiple, scenario probability weights, scorecard weights, and which valuation models are prioritized — is calibrated for BIIB.
